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Single Nucleotide PolymorphismThe Cannabinoid Receptor 2 (CB2R) is a G protein-coupled receptor (GPCR) investigated intensively as
therapeutic target, however no drug has reached the market yet. We investigated personal differences
in CB2R drug responses using a label-free whole-cell assay (xCELLigence) combined with cell lines
(Lymphoblastoid Cell Lines) from individuals with varying CB2R genotypes. Responses to agonists, partial
agonists and antagonists of various chemical classes were characterized. Endogenous cannabinoids such
as 2-AG induced cellular effects vastly different from all synthetic cannabinoids, especially in their
time-profile.
Secondly, the Q63R polymorphism affected CB2R responses in general. Agonists and especially partial
agonists showed higher efficacy in a Q63R minor homozygote versus other genotypes. Non-classical
cannabinoid CP55940 showed the most pronounced personal effects with highly reduced potency and
efficacy in this genotype. Contrarily, aminoalkylindole compounds showed less individual differences.
In conclusion, a label-free whole-cell assay combined with personal cell lines is a promising vehicle to
investigate personal differences in drug response originating from genetic variation in GPCRs. Such
phenotypic screening allows early identification of compounds prone to personal differences (‘precision
medicine’) or more suited as drugs for the general population.
 2017 The Authors. Published by Elsevier Inc. This is anopenaccess article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction for instance as therapeutic target for novel immunomodulators [1].The Cannabinoid Receptor 2 (CB2R) is a class A G Protein-
Coupled Receptor (GPCR) which has been investigated intensively,The Cannabinoid receptor family consists of CB1R, CB2R and as of
late, the former orphan receptors GPR55 and GPR18. Together with
their endogenous ligands, they form part of the endocannabinoid
system which is involved in many physiological processes. CB2R
is a (predominantly) Gai-coupled receptor which is expressed
mainly in cells of the immune system, such as T- and
B-lymphocytes, as well as the central and peripheral nervous
system and the gastrointestinal tract [1–3]. As such, the CB2R is
involved in a wide range of pathological conditions ranging from
atherosclerosis [4], neuropathic pain [5], neurodegenerative dis-
eases [6], osteoporosis [7] and autoimmune diseases [8] to cancer
[9–11]. Hence, the CB2R has been in the focus of drug development
efforts for over a decade. However, no selective drug targeting the
CB2R has made it to the market as of yet. There can be several
reasons as to why drugs fail in clinical trials, one of which is
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most widely prescribed and sold drugs, the so-called big ‘block-
buster’ drugs, only work in 35–75% of all patients [12], as individ-
ual drug response varies due to differences in genetics, lifestyle and
environment. Therefore, personalized or precision medicine aims
to personalize drug prescriptions based on a patient’s individual
characteristics, e.g. genetic information, and thereby decreases
risks of ineffective dosing or side-effects [13,14]. An abundant
source of genetic variation in humans is Single Nucleotide Poly-
morphism (SNP), which can lead to an alteration in the amino acid
sequence of a protein [15]. Many polymorphisms have been docu-
mented in the CB2R, including three that change the amino acid
sequence and occur highly frequently in the population, namely
Q63R, Q66R and H316Y [16]. Of these, both Q63R and H316Y have
been linked to various pathological conditions. Q63R is special, as it
can be caused by a SNP (rs2501432) as well as a dinucleotide poly-
morphism (rs35761398). Q63R has been shown to be involved in
schizophrenia and depression [17–19], alcoholism [20], eating dis-
orders [21], early menarche in obesity [22] and various immune
system related disorders [23–25], while H316Y has been associ-
ated with lowered bone mineral density [26].
We investigated personal differences in CB2R drug responses
using a sensitive in vitro assay, i.e. a label-free cellular assay using
the xCELLigence system, in combination with personal cell lines.
With the xCELLigence, whole-cell responses are measured non-
invasively allowing for the investigation of drug responses in an
unbiased way, i.e. without selecting one signaling pathway or
effect. The personal cell lines used in this study were Lymphoblas-
toid Cell Lines (LCLs) obtained from participants of the Netherlands
Twin Register (NTR), which are derived from B-lymphocytes and
thus endogenously express the CB2R [27,28]. Using LCLs from indi-
viduals with different CB2R genotypes, we tested a number of
ligands ranging from agonists and partial agonists to antagonists
(Fig. 1), which have potential use in different pathological indica-
tions. Firstly, endogenous cannabinoids are fatty acid derivativesFig. 1. Chemical structures of CB2R ligansuch as the eicosanoids 2-AG (2-Arachidonoylglycerol), the main
endogenous ligand for CB2R, and AEA (anandamide) [29,30]. Syn-
thetic cannabinoids can be divided into classical and non-
classical, such as JWH133 and CP55940, respectively. Another large
class of synthetic cannabinoid receptor ligands are the
aminoalkylindoles, of which WIN55212-2 is the most studied ago-
nist and AM630 is one of the most utilized CB2R antagonists [1,31].
Several classes also contain partial agonists, such as aminoalkylin-
dole GW405833 or BAY59-3074, which belongs to a separate
chemical class.
In this study, we show that the xCELLigence in combination
with these personal cell lines can be successfully applied to
investigate personal differences in drug response originating
from, for instance, genetic variation in GPCRs. We furthermore
demonstrate that while certain classes of CB2R ligands show
individual differences, others deliver consistent effects indepen-
dent of genotype. Thus while taking personal medical effects into
account, it is still possible to identify potential ‘blockbuster’
drugs by using such phenotypic screening methods with per-
sonal cell lines.2. Material and methods
2.1. Chemicals and reagents
Fibronectin from bovine plasma, Roswell Park Memorial Insti-
tute (RPMI) 1640 cell culture medium (25 mMHEPES and NaHCO3)
and Pertussis Toxin (PTX) were purchased from Sigma Aldrich
(Zwijndrecht, NL). CB2R ligands AM630, GW405833 and CP55940
were purchased from Sigma Aldrich, BAY59-3074, WIN55212-2
mesylate, JWH133 and AEA from Tocris Bioscience (Bristol, UK)
and 2-AG from Cayman Chemicals (Ann Arbor, MI, USA). All other
chemicals and reagents were of analytical grade and obtained from
commercial sources, unless stated otherwise.ds characterized in this manuscript.
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For all participants of the Netherlands Twin Register (NTR, VU,
Amsterdam, NL) [27] included in this study, lymphoblastoid cell
lines (LCLs) were generated in accordance with a previous publica-
tion [32,33] by the Rutgers University Cell and DNA Repository
(Department of Genetics, Piscataway, NJ, USA). According to a stan-
dard transformation protocol [27], peripheral B-lymphocytes were
transformed with Epstein-Barr Virus (EBV) by treatment with fil-
tered medium from a Marmoset cell line in the presence of phyto-
hemagglutinin during the first week of culture [34–36]. EBV
transformed lymphocytes were expanded by culture for 8–
12 weeks and subsequently cryopreserved.
2.3. Cell culture
LCLs from a family of four individuals, two parents (i.e. geneti-
cally unrelated; individual 2 and 3) and their monozygotic twin
children (i.e. genetically equal; individual 4 and 5), as well as one
other unrelated individual (individual 1) were used for the exper-
iments presented in this manuscript. Individual 2 and 3 have been
part of a previous article [32], where we published effects of
JWH133, AM630 as well as PTX inhibition of JWH133. These data
were incorporated in the current manuscript to allow direct com-
parison to effects of other compounds, individuals and genotypes.
The LCLs were cultured as described previously [32]. In short, LCLs
were cultured as suspension cells in RPMI 1640 (25 mM HEPES and
NaHCO3) supplemented with 15% Fetal calf serum (FCS), 50 mg/ml
streptomycin, 50 IU/ml penicillin, at 37 C and 5% CO2. Cells were
subcultured twice a week at a ratio of 1:5 on 10 cm ø plates and
disposed after maximally 120 days.
2.4. qPCR
For qPCR analysis of receptor expression, RNA of three indepen-
dent samples of each cell line was isolated by RNeasy Plus Mini
(QIAGEN, Venlo, the Netherlands) and cDNA was randomly primed
from 500 ng of total RNA using ReverstAid H Minus First Strand
cDNA synthesis Kit (ThermoFisher, Breda, The Netherlands). The
primer list is included in Table 1. Real-time qPCR was performed
in triplicate for each sample using SYBR Green PCR (Applied
Biosystems, part of ThermoFisher) on a 7500 Real-Time PCR Sys-
tem (Applied Biosystems). qPCR data were collected and analyzed
using SDS2.3 software (Applied Biosystems). Household gene b-
actin was used as internal control to normalize receptor expression
and compare between individuals. Relative mRNA amounts after
correction for b-actin control mRNA were expressed using the
2DDCt method.
2.5. Label-free whole-cell analysis (xCELLigence RTCA system)
2.5.1. Instrumentation principle
Cellular assays using the xCELLigence RTCA system [37] were
performed in accordance with previously published protocols
[32,38]. The real-time cell analyzer (RTCA) uses a detection system
based on electrical impedance to measure the whole-cell







GPR18 AACGGGGGAGAACAGTTACAbottom of the microelectronic E-plates changes the local ionic
environment at the electrode-solution interface, which generates
impedance. Relative changes in impedance (Z) are recorded in
real-time and summarized in the Cell Index (CI). This CI, which is
a dimensionless parameter, is defined at any given time point as
(Zi  Z0)X/15X. Zi is the impedance at each individual time point,
whereas Z0 is defined as 0, as it represents the baseline impedance
in the absence of cells measured prior to the start of the experi-
ment. Impedance and the corresponding CI increase proportionally
as cell adhere to the electrodes. The impedance profile directly
reflects any changes in degree of adhesion, cell number, viability
and morphology [37,39]. As such cellular parameters are also
affected upon activation of GPCR signaling, this allows real-time
monitoring of cellular signaling events [37].
2.5.2. General protocol
xCELLigence assays on LCLs were performed as described previ-
ously [32] with some minor modifications. Briefly, cells were
seeded onto fibronectin-coated E-plates (10 lg/ml) at 50,000
cells/well, unless stated otherwise. Cell counts were performed
with Trypan blue staining on a BioRad TC10 automated cell coun-
ter. E-plates were clicked in the xCELLigence recording station in
an incubator (37 C, 5% CO2). Impedance was measured overnight
for 18 h, after which the cells were stimulated with a cannabinoid
receptor agonist or vehicle control in 5 ll, unless specified other-
wise. As compound solubility required addition of dimethylsulfox-
ide (DMSO) or acetonitrile (ACN), the final concentration upon
ligand or vehicle addition was kept at 0.25% DMSO or respectively
1% ACN for all wells and assays.
For agonist screening purposes, cells were stimulated with ago-
nist concentrations corresponding to approximately 100  pub-
lished pKI values for hCB2R [40,41]. Agonist or partial agonist
concentration-effect curves were generated by stimulating cells
with increasing concentrations of the respective compound. For
antagonist assays, cells were pre-incubated for 30 min with 5 ll
of vehicle control or the respective antagonist at increasing con-
centrations. Subsequently, cells were challenged with a submaxi-
mal agonist concentration of reference full agonist JWH133 equal
to the agonist’s EC80 concentration (100 nM) or vehicle control.
Of note, for partial agonist curves, fibronectin coating was
increased (50 lg/ml) and cells were seeded at a higher density of
100,000 cells/well in order to achieve a sufficient window. To allow
comparison, full agonist JWH133 was always tested alongside all
partial agonists under equal conditions. For endocannabinoids,
addition of the protease inhibitor phenylmethylsulfonyl fluoride
(PMSF) to prevent possible degradation was tested, but as this
did not change the responses or time-profile it was further omitted
(data not shown).
For studies on Gai coupling, cells were seeded in assay medium
containing 100 ng/ml Pertussis Toxin (PTX) or vehicle control, and
stimulated after 18 h with agonist at corresponding EC80 concen-
tration or vehicle control.
2.6. Data analysis
Data were analyzed as published previously [32]. Experimental






J.M. Hillger et al. / Biochemical Pharmacology 130 (2017) 60–70 63San Diego, CA, USA), in which ligand responses were normalized to
the last time point prior to compound addition resulting in the D
Cell Index (Delta Cell Index or D CI). Data were exported to Graph-
Pad Prism 6.0 (GraphPad Software Inc., San Diego, CA, USA) for fur-
ther analysis. Correction for any ligand-independent effects was
achieved by subtracting vehicle control as baseline. Peak responses
were defined as highest D CI (Max D CI) observed within 30 min
after compound addition. For negative impedance responses of 2-
AG, Max-Min D CI within 1 h was used, which is the amplitude
between the highest and lowest D CI. Peak values and experimen-
tal D CI traces were used for construction of bar graphs or concen-
tration–effect curves by nonlinear regression and calculation of
IC50 (half maximal inhibitory concentration), EC50 (half maximal
effective concentration) and EC80 (80% maximal effective concen-
tration) values. Emax (maximum effect) values of compounds were
derived from maximal responses within the analyzed timeframe.
Agonist and partial agonist curves of all individuals as well as the
derived Emax values were normalized to Emax of CB2R-selective ago-
nist JWH133 response on individual 1, first as this individual also
showed the highest response for all agonists with the exception
of CP55940, and secondly as this was also the only case of a single
individual per genotype (only minor homozygote for Q63R, R63).
All values obtained are means of at least three independent
experiments performed in duplicate, unless stated otherwise.
When comparing multiple means or multiple instances of two
means, statistical significance was calculated using a two-way
analysis of variance (ANOVA) with Fisher’s LSD test, for example
comparison of multiple EC50 values or antagonist inhibition of mul-
tiple compounds. Comparison of multiple means to one value was
performed with a two-way ANOVA with Dunnett’s post hoc test,
for instance comparison of JWH133 Peak D CI response after pre-
incubation with various antagonists.2.7. Processing of SNPs and genetic data
As stipulated in a previous publication [33], SNP data for the
NTR individuals included in this study were obtained from the
Genomes of the Netherlands consortium (GoNL; http://www.nlge-
nome.nl/) of which the NTR is part of [42] and analyzed in-house
using PLINK, an open-source whole genome association analysis
toolset (PLINK v1.07, http://pngu.mgh.harvard.edu/purcell/plink/)
[43]. All SNPs within the boundaries of the CNR2 gene (Ensembl
gene: ENSG00000188822) as defined by human genome overview
GRCh37 were analyzed further. Based on GRCh37 and dbSNP infor-
mation (http://www.ncbi.nlm.nih.gov/SNP/), SNPs were annotated
according to position (e.g. coding sequence, exon) and SNP type
(e.g. missense).Fig. 2. Cannabinoid receptor subtype mRNA expression in LCLs. Results of real-time qP
expression of four cannabinoid receptor genes per individual (A–E for individual 1–5, re
ANOVA Fisher’s LSD test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Exp
differences between individuals were for CNR2: # = individual 1 with *to 3,5 and ***to 4. F
with ****to 2,4,5.2.8. Data access
The LCLs used in this study were kindly provided within the
framework of this collaboration [27] and are part of the Netherlands
Twin Register (NTR; http://www.tweelingenregister.org/en/), and
part of the Center for Collaborative Genomic Studies on Mental
Disorders (NIMH U24 MH068457-06). Data and biomaterials
(such as cell lines) are available to qualified investigators, and
may be accessed by following a set of instructions stipulated on
the National Institute of Mental Health (NIMH) website (https://
www.nimhgenetics.org/access_data_biomaterial.php).3. Results
3.1. LCLs predominantly express CB2R
To confirm the suitability of LCLs for studies of CB2R function
alone, RNA expression levels of the four receptors belonging to
the cannabinoid family were assessed by qPCR. These results
showed that mRNA of all four cannabinoid receptors is present in
LCLs to a similar degree, both compared between receptors and
between individuals. There were however some differences. For
instance, GPR18 was expressed higher in many individuals, though
not statistically significant in all. The corresponding expression
data are summarized in Fig. 2. We used the xCELLigence to further
confirm the presence or absence of the different cannabinoid
receptor subtypes, specifically CB2R, by testing selective and non-
selective cannabinoid agonists and antagonists using the LCL of
one exemplary individual (individual 4). To ensure full receptor
occupancy, we tested the compounds at concentrations corre-
sponding to approximately 100 their Ki value at the respective
receptor [40,41]. The agonists tested included selective CB2R ago-
nist JWH133 as well as non-selective agonists CP55940 and
WIN55212-2, which are both known to activate CB1R as well as
CB2R. Neither of these three compounds are GPR18 agonists [44].
These agonists were also chosen as they represent three distinct
chemical classes (Fig. 1). Ligand-induced changes in impedance
were recorded in real-time, of which an example of resulting xCEL-
Ligence traces is shown in Fig. 3. A full real-time trace of a com-
plete experiment is shown in Fig. 3A, and the corresponding
vehicle-corrected compound responses are summarized in Fig. 3B.
LCL seeding resulted in an initial quick increase in impedance
related to cell adhesion, after which cells were allowed to prolifer-
ate and adjust for 18 h (Fig. 3A). Subsequent addition of the ago-
nists induced an immediate increase of impedance to a peak
which gradually decreased towards a plateau within 30 min
(Fig. 3B). The responses of all three agonists were highly similarCR (three independent samples measured in triplicate, mean ± SEM) show mRNA
spectively). Significant differences in expression were determined with a two-way
ression differences within each individual are indicated in the figure. Expression
or GPR18 these were: y = individual 1 with *to 2; **to 5; ****to 4 and § = individual 3
Fig. 3. Cannabinoid receptor ligand screen to determine receptor subtype expression. Representative real-time traces of (A) a full experiment and (B) baseline-corrected
responses in a screen of cannabinoid agonists and antagonist. (C) Corresponding maximal responses of the screen (Max D Cell Index or Max D CI), normalized to response to
CB2R-selective agonist JWH133. Concentrations used were JWH133 [1 lM], WIN55212-2 [10 lM], CP55940 [1 lM], AM630 [10 lM] and GPR55 agonist AM251 [10 lM]. All
data shown were obtained with the LCLs of individual 4. (D) Inhibition of agonist effects by CB2R specific antagonist AM630 in LCLs of individual 4, normalized to peak D CI of
untreated agonist response. LCLs were pre-incubated with AM630 [10 lM] 30 min before stimulation with agonist at EC80 (JWH133 [100 nM], WIN55212-2 [10 nM], CP55940
[10 nM]). Degree of inhibition did not differ significantly between agonists, as determined by two-way ANOVA with Fisher’s LSD post-hoc test. (E) Individual AM630
concentration-effect curve obtained from peak D CI of the baseline-corrected JWH133 response antagonized by increasing concentrations of AM630. Antagonist potency
values were 6.76 ± 0.04, 6.77 ± 0.06, 6.85 ± 0.04, 6.90 ± 0.05 and 6.77 ± 0.04 for individuals 1–5, respectively. No statistically significant differences between individuals were
observed as determined by two-way ANOVA with Fisher’s LSD post-hoc test. (F) Inhibition of agonist-induced Gai downstream signaling by pretreatment with PTX in LCLs of
individual 4, normalized to peak D CI of untreated agonist response. LCLs were seeded in presence or absence of PTX [100 ng/ml] and treated with agonist at EC80 after 18 h
growth. Degree of inhibition did not differ significantly between agonists, as determined by two-way ANOVA with Fisher’s LSD post-hoc test. (G) Individual effect of Gai
inhibition by PTX on CB2R response to agonist JWH133. Response in the presence of PTX versus JWH133 alone was highly significantly reduced within each individual (****).
Statistical differences between individuals were determined by two-way ANOVA with Fisher’s LSD post-hoc test. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.
Data represent mean ± SEM obtained from three or four (B, C, E, G) independent experiments of performed in duplicate. For (D, F) data represent mean ± SD from two
independent experiments performed in duplicate from individual 4, used as representative example here, while results on other individuals (2, 3, 5) were comparable (data
not shown). #AM630 curves and PTX inhibition for individuals 2 and 3 had been previously established [32] but were incorporated to allow direct comparison.
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were mediated through the same receptor. AM251, which is
known to be a GPR55 full agonist, partial GPR18 agonist and
CB1R antagonist [44], gave little to no response. This indicates that
the actual protein expression of these receptors is absent or too
low to contribute to any of the compound responses measured
here.
Furthermore, a CB2R-selective antagonist, aminoalkylindole
AM630 was tested as well to confirm that agonist responses were
indeed CB2R-mediated. While AM630 gave little to no response on
its own, it was able to significantly block responses of all agonists
at a concentration of 100  Ki. The level of blockade did not differ
significantly between agonists, irrespective of their receptor selec-
tivity (Fig. 3D). Furthermore, comparable AM630 effects were
observed on LCLs from other individuals. For instance, AM630
showed strong inhibition with a clear concentration-effect rela-
tionship that did not differ in potency between the five individuals
tested and ranged from 6.76 ± 0.04 to 6.90 ± 0.05 (Fig. 3E).
Finally, the effect of pertussis toxin (PTX) pre-treatment was
investigated to confirm downstream signaling through Gai. PTX
caused a significant decrease in cellular responses of all three ago-
nists for individual 4, which was to a similar degree as AM630(Fig. 3F). In addition, inhibition of the agonist JWH133 by PTX
was strong in all five individuals, with some differences in the level
of remaining effects ranging from 7.6 ± 3.6% up to 35.5 ± 8.9%
(Fig. 3G). Taken together, the agonist, antagonist and PTX effects
confirm that CB2R signaling can be measured sensitively and
specifically in these LCLs.3.2. Individual differences in CB2R synthetic agonist responses in LCLs
Following the confirmation that cellular effects were specifi-
cally CB2R-related, agonist concentration-effect curves were stud-
ied on LCLs from five individuals. Individuals 2 and 3 are the
parents of individuals 4 and 5, their monozygotic twin children,
while individual 1 is unrelated. Examining their genotypes from
DNA sequence data revealed that individual 1 is a homozygote
for the minor allele (genotype GG thus R63) for Q63R polymor-
phism (rs35761398), while individuals 2 and 3 are heterozygotes
and individuals 4 and 5 are homozygotes for the major allele
(genotype AA thus Q63) (see also Table 2, 3), representing the most
common genotype among the human population (http://www.
ncbi.nlm.nih.gov/SNP/).
Table 2
Individual potencies of all CB2R (partial) agonists. Statistically significant differences between individuals were determined by two-way ANOVA with Fisher’s LSD post-hoc test.
* = p < 0.05; ** = p < 0.01; **** = p < 0.0001.
Individual JWH133 WIN55212-2 CP55940 2-AG AEA GW405833 BAY59-3074
pEC50 ± SEM pEC50 ± SEM pEC50 ± SEM pEC50 ± SEM pEC50 ± SEM pEC50 ± SEM pEC50 ± SEM




6.76 ± 0.08 7.99 ± 0.09
*to 2 **to 3
7.67 ± 0.09
*to 4 ****to 2,5
2 (Parent 1; Q/R63) 7.82 ± 0.07a 8.65 ± 0.12 8.93 ± 0.05
****to 1
5.65 ± 0.06






*to 4,5 **to 3 ****to 1









**to 2, ****to 5
4 (Twin 1; Q63) 7.90 ± 0.08
*to 5
8.62 ± 0.18 8.90 ± 0.04
****to 1
5.69 ± 0.02
*to 1,5 ****to 3
6.75 ± 0.07 7.76 ± 0.08 8.00 ± 0.04
*to 1,2 ****to 5
5 (Twin 2; Q63) 7.67 ± 0.05
*to 4




6.76 ± 0.16 7.95 ± 0.13
*to 2 **to 3
8.54 ± 0.12
*to 2 ****to 1,3,4
aJWH133 curves for individuals 2 and 3 have been previously established [32] and data were incorporated to allow direct comparison.
Table 3
Individual efficacies of all CB2R (partial) agonists. All efficacies are in reference to the standard CB2R-selective agonist JWH133 tested on the individual that was the only minor
homozygote for Q63R (R63), individual 1, with exception of 2-AG which was normalized to maximal 2-AG effect on individual 1 as explained in text. Statistically significant
differences between individuals were determined by two-way ANOVA with Fisher’s LSD post-hoc test. * = p < 0.05; ** = p < 0.01; *** = p < 0.001, **** = p < 0.0001.
Individual JWH133 WIN55212-2 CP55940 2-AG AEAa GW405833a BAY59-3074a
Emax ± SEM Emax ± SEM Emax ± SEM Emax ± SEM Emax ± SEM Emax ± SEM Emax ± SEM
1 (Unrelated; R63) 100 ± 4.2
*to 4 **to 3 ***to 2
110.1 ± 5.4








*to 2,4,5 **to 3
71.9 ± 5.9
*to 2,4 **to 3,5
2 (Parent 1; Q/R63) 62.4 ± 1.8b
***to 1,5
38.5 ± 5.3












3 (Parent 2; Q/R63) 72.5 ± 7.7b
**to 1,5
42.4 ± 4.3












4 (Twin 1; Q63) 77.9 ± 4.1
*to 1,5
77.3 ± 9.9
*to 1 ***to 2,3
74.1 ± 6.8
*to 1,5 **to 3 ***to 2
82.9 ± 4.4







5 (Twin 2; Q63) 98.8 ± 10.9
*to 4 **to 3
***to 2
83.2 ± 13.3











aAs opposed to the full agonists, experiments with partial agonists AEA, GW405833 and BAY59-3074 were performed with more coating (Fibronectin 50 lg/ml) and higher
cell density (100,000 cells/well) in order to obtain a sufficient window.
bJWH133 curves for individuals 2 and 3 have been previously established [32], data were incorporated to allow direct comparison.
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compounds, typically referred to as full agonists, from different
chemical classes, JWH133, WIN55212-2 and CP55940. Example
xCELLigence traces of the JWH133 concentration-effect relation-
ship are given in Fig. 4A. The resulting concentration-effect curves
are summarized in Fig. 4B–D. Corresponding pEC50 values are sum-
marized in Table 2 while Emax values are given in Table 3.
As can be observed from the curves and pEC50 values (Table 2),
potencies for the three agonists were similar for all individuals,
with a notable exception for CP55940 on individual 1 (Fig. 4D).
For this individual, who is the only minor homozygote for Q63R,
CP55940 showed a significantly increased EC50 value of approxi-
mately 10-fold. In contrast, the efficacy of all three agonists was
much more divergent on the different cell lines. Interestingly,
WIN55212-2 which showed no significant differences in potency,
showed a significant spread in efficacy corresponding to genotype
(Fig. 4C, Table 3). WIN55212-2 had the lowest efficacy on the two
heterozygous individuals 2 and 3, which in fact made it a partial
agonist on these cell lines in comparison to JWH133 (Table 3).
For the other three individuals, WIN55212-2 had a similar efficacy
to JWH133, and both compounds had the highest efficacy on the
LCLs of individual 1. The two synthetic cannabinoids JWH133
and CP55940 showed differences in efficacy that did not correlate
with genotype. However, compared to JWH133, CP55940 had a
lower efficacy in all individuals making it a partial agonist, with
exception of individual 4. Even on individual 1 CP55940 was a par-
tial agonist, where for all other tested agonists the highest efficacywas found. Taken together, CP55940 was the only synthetic agonist
with clear individual differences related to genotype (i.e. a
decreased potency and efficacy in presence of R63), while
aminoalkylindole WIN55212-2 was the least prone to individual
variation.
3.3. Endogenous agonist induces different cellular response than
synthetic agonists
To test whether signaling caused by endogenous agonists also
showed individual differences, the response induced by the two
main endogenous CB2R ligands, eicosanoid 2-AG and AEA, known
as full and partial CB2R agonists respectively, were examined. In
order to allow a sufficient response window to characterize partial
agonist AEA, conditions were optimized by seeding more cells
(100,000 cells/well) and coating with more fibronectin (50 lg/
ml). Both full agonist JWH133 and 2-AG were also tested under
these adjusted conditions, and the responses of JWH133 were used
as reference compound to determine the level of partial agonism.
Interestingly, the resulting real-time trace differed significantly
from all synthetic agonists, as shown in Fig. 5A, B. While all syn-
thetic agonists induced an immediate positive impedance change,
which was characterized by a fast peak and subsequent decline to
baseline in around 30 min, the endogenous 2-AG induced a nega-
tive change in impedance with a much slower onset after about
20 min, and a much more prolonged response that still persisted
after 180 min (Fig. 5A). Interestingly, AEA showed a similar time-
Fig. 4. Individual CB2R responses to full agonists of three distinct chemical classes. Cell lines were stimulated with different concentrations of full agonist JWH133,
WIN55212-2 or CP55940 18 h after seeding (50,000 cells/well). (A) Representative graph of the baseline-corrected JWH133 response [1 lM – 100 pM] from individual 1.
Concentration-effect curves of all individuals (1–5) of (B) classical cannabinoid JWH133 (C) aminoalkylindole WIN55212-2 and (D) non-classical cannabinoid CP55940
obtained from Max D CI, normalized to Emax of CB2R-selective agonist JWH133 response on individual 1. Data represent mean ± SEM obtained from three or four independent
experiments performed in duplicate. #JWH133 curves for individuals 2 and 3 have been previously established [32] but were incorporated to allow direct comparison.
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induced a positive impedance change like the synthetic cannabi-
noids, albeit with a different shape (Fig. 5B). Thus, endogenous
agonist signaling through CB2R lead to vastly different cellular
changes than any of the synthetic agonists. To confirm whether
these effects were also CB2R-mediated, we showed that the 2-AG
response is blocked by CB2R-selective antagonist AM630, similar
to the synthetic agonists (Fig. 5E). Moreover, downstream signaling
via Gai was inhibited by PTX pre-treatment as well (Fig. 5F). Of
note, AM630 blockade and PTX inhibition did not differ signifi-
cantly between individuals, even with opposing Q63R genotype,
as demonstrated in the LCLs of individuals 1 and 4 (Fig. 5E, F).
Furthermore, the concentration-effect relationship of 2-AG
showed significant differences between the five individuals, which
were within half a log-unit and therefore smaller than those
observed for CP55940. However, these differences in potencies
were not consistent with the presence of Q63R (Fig. 5C, Table 2).
Interestingly, the differences in efficacy of 2-AG were consistent
with genotype (Table 3), as the efficacy in heterozygous individuals
2 and 3 was significantly lower than for all other individuals. Any
differences observed for AEA were not CB2R genotype-related
(Fig. 5D, Table 2, 3). In summary, especially signaling by the main
CB2R endogenous ligand 2-AG lead to different cellular changes
as opposed to synthetic agonists, and showed a genotype effect
on efficacy as it appeared to be highest in the R63 homozygote,
but lowest in Q63R heterozygotes.
3.4. Partial agonist responses differ between individuals
Subsequently, two partial CB2R agonists were tested on all five
individuals to investigate the presence of any differences in indi-
vidual effects possibly linked to the Q63R genotype. Once again,conditions were adjusted to more cells (100,000 cells/well) and
fibronectin (50 lg/ml) to allow a sufficient response window for
these partial agonists. JWH133 was also tested under these
adjusted conditions as reference compound to determine the level
of partial agonism. The two partial agonists tested were
aminoalkylindole GW405833 and BAY59-3074, which belongs to
a separate chemical class (Fig. 1). In all individuals, both agonists
induced positive impedance responses like the synthetic full ago-
nists, and demonstrated clear partial agonistic behavior in compar-
ison to JWH133, irrespective of genotype (Fig. 6A and B). The
concentration-effect curves are represented in Fig. 6C and D, while
the resulting pEC50 and Emax values are summarized in
Tables 2 and 3, respectively. GW405833 showed significant differ-
ences in potency which were within half a log-unit and were not
entirely consistent with genotype. However, the individual poten-
cies for BAY59-3074 showed a larger spread close to a full log-unit.
The lowest potency was observed on individual 1, though this sta-
tistical difference was not genotype consistent. In terms of efficacy,
BAY59-3074 had a higher efficacy than GW405833 for all individ-
uals. Interestingly, the Emax value of GW405833 on the LCLs of indi-
vidual 1 (i.e. presence of R63) was significantly higher than that on
all other individuals (Table 3), which was also observed for BAY59-
3074. Taken together, the partial agonists showed personal differ-
ences in response, which (in part) appeared to be compound speci-
fic and less pronounced for the aminoalkylindole GW405833.
4. Discussion
CB2R is considered a potential therapeutic target for immune
system related disorders such as multiple sclerosis and allergy
[45], neuropathic pain [46], cancer and osteoporosis [1,45]. As
genetic differences between individuals can induce large variations
Fig. 5. Individual CB2R responses to endocannabinoids. Cell lines were stimulated with 2-AG (50,000 cells/well, fibronectin 10 lg/ml) or AEA (100,000 cells/well, fibronectin
50 lg/ml) 18 h after seeding. Representative graphs of the baseline-corrected (A) 2-AG [10 lM – 3.16 nM] and (B) AEA [10 lM – 1 nM] response from individual 1. (C)
Concentration-effect curves of 2-AG were obtained from Max-Min D CI within 1 h of stimulation were normalized to Emax on individual 1. (D) Concentration-effect curves of
AEA were obtained from Max D CI normalized to Emax of CB2R-selective agonist JWH133 response on individual 1. Next, bar graphs show the inhibition of the 2-AG effect by
(E) CB2R-selective antagonist AM630 [10 lM] and (F) Gai-inhibitor PTX normalized to 2-AG’s effect at EC80 (3.16 lM). Data represent the means ± SEM from three or four (C,
D) or means ± SD of two (E, F) independent experiments performed in duplicate. Significance of inhibitor effect versus 2-AG response only was determined with a two-way
ANOVA Fisher’s LSD test * = p < 0.05, ** = p < 0.01. AM630 and PTX inhibition did not differ significantly between individuals 1 (R63) and 4 (Q63) as determined using a two-
way ANOVA with a Sidak post-hoc test.
Fig. 6. Individual CB2R responses from two partial agonists. Cell lines were stimulated with agonist 18 h after seeding (100,000 cells/well, fibronectin 50 lg/ml).
Representative graph of the baseline-corrected response to (A) GW405833 and (B) BAY59-3074 [1 lM – 100 pM] from individual 1. Resulting concentration-effect curves of
(C) GW405833 and (D) BAY59-3074 obtained from peak D CI normalized to JWH133 [1 lM] effect on individual 1. Data represent mean ± SEM obtained from three
independent experiments performed in duplicate.
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CB2R ligands with a panel of personal cell lines, the LCLs, from indi-
viduals with varying CB2R genotypes. These included genetically
unrelated individuals as well as monozygotic twins, who are
deemed genetically identical. Hence, confirming the comparability
of their responses is a standard way to control for genotype-
unrelated effects [27,47]. The individuals in this study represent
all possible genotypes for the polymorphism Q63R. Even though
this polymorphism is present in roughly half of the population
and thus is extremely common, it has also been associated with
various pathological disorders [17–19,22–25]. This makes charac-
terizing the impact of this polymorphism on drug responses an
important issue for CB2R drug discovery.
We characterized the genotype-effect on responses of several
individuals by applying label-free cellular assay technology,
namely the impedance-based xCELLigence apparatus. Such tech-
nologies allow sensitive non-invasive assays that enable the inves-
tigation of GPCRs in endogenous cell systems, including LCLs for
which we recently published an optimized protocol [32]. The com-
bination of such a non-invasive assay with a personal cell line
offers many advantages over traditional GPCR methodologies. In
general, potencies of all CB2R compounds tested in our research
on the LCLs were within one log-unit range of previously published
values (Table 2) [40,41]. Notable exceptions were 2-AG and
GW405833, which differed from published pEC50 values by up to
17-fold (pEC50 of 6.91 by Gonsiorek et al. [48]) and 43-fold
(pEC50 of 9.19 ± 0.09 by Valenzano et al. [49]), respectively. This
discrepancy is most likely due to differences in cell lines and assay
type. Valenzano et al. [49] used a typical endpoint cAMP accumu-
lation assay in combination with a CHO-K1 system overexpressing
recombinant CB2R, while LCLs represent a more physiological cell
system with endogenous receptor expression. Furthermore, rather
than just being a human cell line with endogenous expression, LCLs
are even one step closer to the physiological situation as they are
directly derived from individual persons. The use of a label-free
whole-cell assay is preferable over typical endpoint assays to min-
imize bias [50], especially when investigating a GPCR with func-
tional selectivity such as the CB2R, in which multiple pathways
can be activated to a different extent [51,52].
Before starting CB2R functional investigations in LCLs, we stud-
ied expression levels and screened functional responses to confirm
receptor subtype presence. All cannabinoid receptors are
expressed in LCLs at mRNA level (Fig. 2) with some differences
between individuals. However, these did not correspond to the
general differences we observed in compound potency or efficacy
(Tables 2, 3). For example for CB2R, mRNA expression differed for
individual 1, especially as opposed to individual 4. However, both
individuals were among the highest responders on average for
CB2R compounds (Table 3). Furthermore, most individuals showed
high GPR18 mRNA levels, but AM251 which targets GPR18 and
GPR55 but not CB2R, showed no response (Fig. 3) [48]. This indi-
cates that functional GPR18 levels were in fact not high, if at all
present in these LCLs, which shows that mRNA expression levels
do not necessarily correlate with functional protein expression
on the cellular membrane, a feature well appreciated in literature
[53,54]. Taken together, the data shown in Fig. 3 prove that CB2R
is in fact the major receptor responsible for compound responses,
which is in accordance with previous literature that states CB2R
is the highest expressed receptor in LCLs [28]. Of note, any of the
full agonists tested in this manuscript such as WIN5512-2,
JWH133, CP55940 and 2-AG are not known as agonists of GPR18
[44].
After confirming that CB2R is well expressed in LCLs and that
CB2R signaling can be measured sensitively and specifically in LCLs
(Figs. 2, 3), we characterized responses of five individuals to
various CB2R ligand types and classes (Fig. 1) which revealed thatcertain chemical classes of compounds were more sensitive to
genotype than others (Figs. 4–6, Tables 2, 3). All tested
aminoalkylindole compounds as well as the classical cannabinoid
JWH133 showed the least differences between individuals, in com-
parison to compounds of other chemical classes. The notion that
aminoalkylindole compounds showed the least genotype-related
effects was strengthened by testing three pharmacological types
of ligands of this chemical class. Similar to the aminoalkylindole
agonist, no individual differences were observed for the CB2R-
selective antagonist AM630 (Fig. 3D). Even a partial agonist of this
class (GW405833) was less prone to individual differences than a
partial agonist of another class. It has been suggested that partial
agonists are more sensitive to system-related differences in recep-
tor function, for instance receptor expression or downstream cou-
pling, than full agonists or antagonists [55]. Consequently, they
may be more prone to genotype-related effects. In fact, we have
demonstrated in a previous publication that a partial agonist on
the adenosine A2A receptor showed a clear genotype-related differ-
ence in LCLs, while full agonists did not [33]. The two synthetic
partial agonists for the CB2R that we tested here exhibited similar
sensitivity (Fig. 6, Tables 2, 3). In efficacy, they showed the clearest
genotype-related effect as it was only significantly elevated for the
R63 individual, as opposed to the full agonists where more individ-
uals differed.
Overall, CP55940 showed the most pronounced personal effects
with highly reduced potency and efficacy in presence of R63, while
all other agonists and partial agonists showed the highest efficacy
in presence of this genotype. Interestingly, Q63R has been reported
to cause diminished WIN55212-2 efficacy in HEK293hCB2R cells
while CP55940 was not affected [56]. Our results contradict these
findings, which may be due to the difference in model systems
used. HEK293 cells are recombinant and receptor-overexpressing,
whereas LCLs are personal cell lines with endogenous levels of
receptor expression, and therefore may represent a more physio-
logically relevant system.
When investigating genotype effects on endogenous cannabi-
noid response, we noted that 2-AG showed vastly different cellular
effects than any other ligand tested here, despite being clearly
CB2R-mediated (Fig. 5). Another endocannabinoid, AEA, showed a
similarly changed time-profile as 2-AG, even though the direction
of impedance change was more similar to synthetic cannabinoids.
These differences in cellular effects between endogenous and syn-
thetic cannabinoids may originate from downstream signaling dif-
ferences resulting in a different cellular response as measured by
xCELLigence. For instance, Shoemaker et al. [51] found that 2-AG
was a more potent activator of MAPK whereas synthetic ligands
more potently inhibited adenylyl cyclase activity. Moreover, our
experiments with 2-AG do not suggest that Q63R influences its
responses, which contrasts with previous reports of Carrasquer
et al. [56] and Ishiguro et al. [17], where recombinant overexpress-
ing cell systems, HEK293 and CHO cells, were used. However, our
findings are confirmed by Sipe et al. [8] who used a more physio-
logical setting of T-lymphocytes, as is the case in this study. Taken
all of the above together, this once more highlights the importance
of using primary or derived (i.e. endogenous immortalized) cell
systems that offer more physiological relevance versus recombi-
nant systems.
There are several mechanisms by which a polymorphism may
influence receptor signaling. Q63R in the CB2R results from a din-
ucleotide conversion of AA to GG that exchanges a glutamine for
an arginine at position 63 in the intracellular loop 1, and as such
it is not in proximity of the putative CB2R ligand binding site
[56,57]. Therefore, its position suggests that Q63R does not directly
influence ligand binding. Rather, its effects on drug responses may
originate from differences in downstream signaling [17,56]. CB2R
has been shown to signal through multiple pathways such as
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differently biased [30,58,59]. Moreover, it has been well estab-
lished that agonists can activate the various G protein-dependent
and –independent pathways modulated by CB2R to a different
extent [51,52]. In our LCLs, all CB2R agonists signaled strongly
through Gai coupling as was demonstrated by potent inhibition
through PTX (Figs. 3, 5), which on some instances showed differ-
ences in the levels of remaining response (Fig. 3D). While Gai sig-
naling therefore clearly represents the predominant signaling
pathway for CB2R in all individuals, the varying remaining
responses could indicate individual differences in coupling to other
signaling pathways. Hence, Q63R related differences observed
between CP55940 and other agonists may be related to their speci-
fic bias. Q63R could potentially affect coupling to one signaling
pathway more than others, an effect which is then only noted for
agonists that preferably and potently activate that pathway, in this
case CP55940. Alternatively, Q63R could affect the bias of a partic-
ular ligand as CP55940 towards different signaling pathways.
Another interesting genotype-related effect was that in overall
efficacy (Table 3), R63 homozygous individual 1 generally ranked
highest. Q63R heterozygotes (ind. 2 and 3) appeared to have the
lowest efficacy for CB2R agonists, even compared to Q63 homozy-
gotes (ind. 4 and 5), rather than an intermediate or mixed cellular
effect. This was most pronounced for WIN55212-2 and 2-AG
(Table 3). The effect could arise from, for instance, a difference in
signaling pathway bias between the two receptor forms. In a
heterozygote, where both receptor forms are present that each
have different efficiencies in pathway-coupling, the overall signal-
ing and cellular effect may be lower as opposed to either receptor
form as homozygote, that works synergistically.
In conclusion, our results demonstrate that aminoalkylindole
compounds exhibited the least sensitivity to genotypes while
non-classical cannabinoid CP55940 showed the most. R63 geno-
type influenced CB2R ligand effects leading to higher efficacy of
agonists and especially partial agonists, but decreased potency
and efficacy of the non-classical cannabinoid CP55940, which
was also the most pronounced ‘personal’ effect measured here.
The LCLs, as personal cell lines, in combination with the sensitive
label-free impedance-based technology have the potential to rep-
resent a more physiologically relevant model system to investigate
individual differences in drug response. Their combination pro-
vided novel insights into the impact of CB2R polymorphism on
drug response, which demonstrates on the one hand the ability
of this phenotypic screening method to identify ‘blockbuster’ drug
candidates that are less prone to individual differences. On the
other hand, this approach may advance precision medicine and
stratify patient groups. Altogether, this will help in reducing attri-
tion rates of drugs in clinical trials.Disclosure declaration
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